Recurrent and functional regulatory mutations in breast cancer

Nature

Volumn 547, Issue 7661, 2017, Pages 55-60

  Rheinbay, Esther ^a,b   Parasuraman, Prasanna ^b   Grimsby, Jonna ^a   Tiao, Grace ^a   Engreitz, Jesse M ^a,c   Kim, Jaegil ^a   Lawrence, Michael S ^a,b   Taylor Weiner, Amaro ^a   Rodriguez Cuevas, Sergio ^d   Rosenberg, Mara ^a   Hess, Julian ^a   Stewart, Chip ^a   Maruvka, Yosef E ^a,b   Stojanov, Petar ^a   Cortes, Maria L ^a   Seepo, Sara ^a   Cibulskis, Carrie ^a   Tracy, Adam ^a   Pugh, Trevor J ^e   Lee, Jesse ^b   Zheng, Zongli ^b   Ellisen, Leif W ^b,f   Iafrate, A John ^b   Boehm, Jesse S ^a   Gabriel, Stacey B ^a   Meyerson, Matthew ^a,f,g   Golub, Todd R ^a,f,g   Baselga, Jose ^h   Hidalgo Miranda, Alfredo ⁱ   Shioda, Toshi ^b   Bernards, Andre ^b   Lander, Eric S ^a   Getz, Gad ^a,b,f   more..

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d Instituto de Enfermedades de la Mama FUCAM   (Mexico)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f HARVARD MEDICAL SCHOOL   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOLASE A; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE; DNA FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; LEPTIN RECEPTOR OVERLAPPING TRANSCRIPT LIKE 1; NUCLEAR PARASPECKLE ASSEMBLY TRANSCRIPT 1; RNA COMPONENT OF MITOCHONDRIAL RNA PROCESSING; TBC1 DOMAIN FAMILY MEMBER 12; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; UNTRANSLATED RNA; ZINC FINGER PROTEIN 143; ESTROGEN RECEPTOR; FOXA1 PROTEIN, HUMAN; LONG UNTRANSLATED RNA; NEAT1 LONG NON-CODING RNA, HUMAN; PROTEIN BINDING; RMRP NON-CODING RNA, HUMAN;

ANALYTICAL METHOD; CANCER; COHORT ANALYSIS; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENOMICS; MUTATION; PROTEIN; RNA; TUMOR;

ARTICLE; BREAST CANCER; DISEASE ASSOCIATION; FEMALE; GC RICH SEQUENCE; GEL MOBILITY SHIFT ASSAY; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENOME ANALYSIS; HEK293T CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; MCF-7 CELL LINE; MISSENSE MUTATION; MUTATION RATE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; TUMOR GENE; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; COHORT ANALYSIS; EXOME; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MUTATION;

BREAST NEOPLASMS; COHORT STUDIES; E2F TRANSCRIPTION FACTORS; EXOME; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECEPTORS, ESTROGEN; RNA, LONG NONCODING;

EID: 85022191096     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature22992     Document Type: Article

References (70)

1. Fredriksson, N. J., Ny, L., Nilsson, J. A. & Larsson, E. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nat. Genet. 46, 1258-1263 (2014).
2. Weinhold, N., Jacobsen, A., Schultz, N., Sander, C. & Lee, W. Genome-wide analysis of noncoding regulatory mutations in cancer. Nat. Genet. 46, 1160-1165 (2014).
3. Araya, C. L. et al. Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterations. Nat. Genet. 48, 117-125 (2016).
4. Melton, C., Reuter, J. A., Spacek, D. V. & Snyder, M. Recurrent somatic mutations in regulatory regions of human cancer genomes. Nat. Genet. 47, 710-716 (2015).
5. Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47-54 (2016).
6. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
7. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
8. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
9. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
10. Ciriello, G. et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163, 506-519 (2015).
11. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
12. Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353-360 (2012).
13. Stephens, P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404 (2012).
14. Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405-409 (2012).
15. Getz, G. et al. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science 317, 1500 (2007).
16. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
17. Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970-976 (2013).
18. Kim, J. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet. 48, 600-606 (2016).
19. Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
20. Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma. Science 339, 959-961 (2013).
21. Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957-959 (2013).
22. Huang, W. et al. DDX5 and its associated lncRNA Rmrp modulate TH17 cell effector functions. Nature 528, 517-522 (2015).
23. Standaert, L. et al. The long noncoding RNA Neat1 is required for mammary gland development and lactation. RNA 20, 1844-1849 (2014).
24. Carroll, J. S. et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the Forkhead protein FoxA1. Cell 122, 33-43 (2005).
25. Hurtado, A., Holmes, K. A., Ross-Innes, C. S., Schmidt, D. & Carroll, J. S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 43, 27-33 (2011).
26. Ross-Innes, C. S. et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389-393 (2012).
27. Badve, S. et al. FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin. Cancer Res. 13, 4415-4421 (2007).
28. Thorat, M. A. et al. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J. Clin. Pathol. 61, 327-332 (2008).
29. Mehta, R. J. et al. FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res. Treat. 131, 881-890 (2012).
30. Fu, X. et al. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc. Natl Acad. Sci. USA 113, E6600-E6609 (2016).
31. Jeselsohn, R. et al. TransCONFIRM: identification of a genetic signature of response to fulvestrant in advanced hormone receptor-positive breast cancer. Clin. Cancer Res. 22, 5755 (2016)
32. Fisher, S. et al. A scalable, fully automated process for construction of sequenceready human exome targeted capture libraries. Genome Biol. 12, R1 (2011).
33. Gnirke, A. et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat. Biotechnol. 27, 182-189 (2009).
34. Pugh, T. J., Banerji, S. & Meyerson, M. Pugh et al. reply. Nature 520, E12-E14 (2015).
35. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
36. Cibulskis, K. et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 27, 2601-2602 (2011).
37. Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. 41, e67 (2013).
38. Ramos, A. H. et al. Oncotator: cancer variant annotation tool. Hum. Mutat. 36, E2423-E2429 (2015).
39. Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
40. Landau, D. A. et al. Mutations driving CLL and their evolution in progression and relapse. Nature 526, 525-530 (2015).
41. Purcell, S. M. et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 506, 185-190 (2014).
42. Price, A. L. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38, 904-909 (2006).
43. Gonzalez-Perez, A. & Lopez-Bigas, N. Functional impact bias reveals cancer drivers. Nucleic Acids Res. 40, e169 (2012).
44. Lochovsky, L., Zhang, J., Fu, Y., Khurana, E. & Gerstein, M. LARVA: an integrative framework for large-scale analysis of recurrent variants in noncoding annotations. Nucleic Acids Res. 43, 8123-8134 (2015).
45. Martincorena, I. et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 880-886 (2015).
46. Dees, N. D. et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res. 22, 1589-1598 (2012).
47. Geyer, C. J. & Meeden, G. D. Fuzzy and randomized confidence intervals and P values. Stat. Sci. 20, 358-366 (2005).
48. Routledge, R. Practicing safe statistics with the mid-p. Can. J. Stat. 22, 103-110 (1994).
49. Kamburov, A. et al. Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc. Natl Acad. Sci. USA 112, E5486-E5495 (2015).
50. Getz, G., Gould, J. & Monti, S. Boosting permutation tests for marker selection. Broad Institute publications http://www.broadinstitute.org/mpr/publications/ projects/Computational-Biology/GetzGouldMonti.pdf (2006).
51. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Stat. Soc. B 57, 289-300 (1995).
52. The ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).
53. Matys, V. et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 31, 374-378 (2003).
54. Sandelin, A., Alkema, W., Engström, P., Wasserman, W. W. & Lenhard, B. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 32, D91-D94 (2004).
55. Hallikas, O. et al. Genome-wide prediction of mammalian enhancers based on analysis of transcription-factor binding affinity. Cell 124, 47-59 (2006).
56. Jolma, A. et al. Multiplexed massively parallel SELEX for characterization of human transcription factor binding specificities. Genome Res. 20, 861-873 (2010).
57. Jolma, A. et al. DNA-binding specificities of human transcription factors. Cell 152, 327-339 (2013).
58. Wei, G. H. et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J. 29, 2147-2160 (2010).
59. Touzet, H. & Varré, J. S. Efficient and accurate P value computation for position weight matrices. Algorithms Mol. Biol. 2, 15 (2007).
60. The Cancer Genome Atlas Research. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481-2498 (2015).
61. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
62. Cowper-Sal lari, R. et al. Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat. Genet. 44, 1191-1198 (2012).
63. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576-589 (2010).
64. Fuerer, C. & Nusse, R. Lentiviral vectors to probe and manipulate the Wnt signaling pathway. PLoS ONE 5, e9370 (2010).
65. Cao, L. et al. Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F. Nature 355, 176-179 (1992).
66. Hallstrom, T. C. & Nevins, J. R. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc. Natl Acad. Sci. USA 100, 10848-10853 (2003).
67. Lazzerini Denchi, E. & Helin, K. E2F1 is crucial for E2F-dependent apoptosis. EMBO Rep. 6, 661-668 (2005).
68. Dick, F. A. & Dyson, N. pRB contains an E2F1-specific binding domain that allows E2F1-induced apoptosis to be regulated separately from other E2F activities. Mol. Cell 12, 639-649 (2003).
69. Coser, K. R. et al. Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc. Natl Acad. Sci. USA 106, 14536-14541 (2009).
70. Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24-26 (2011).